Search research articles
Contact Us
Filters
Showing results (201-210 of 234) with videos related to
Page
of 24
Sort By:
The Journal of Infectious Diseases
|
April 9, 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
Chung-Feng Huang, Chao-Hung Hung, Pin-Nan Cheng, et al.
Science Advances
|
January 31, 2020
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
Kuan-Wei Huang, Fu-Fei Hsu, Jiantai Timothy Qiu, et al.
International Journal of Legal Medicine
|
June 17, 2010
The strategies to DVI challenges in Typhoon Morakot
Chun-Yen Lin, Tsun-Ying Huang, Hsuan-Cheng Shih, et al.
Nature Communications
|
October 27, 2022
GPR97 triggers inflammatory processes in human neutrophils via a macromolecular complex upstream of PAR2 activation
Tai-Ying Chu, Céline Zheng-Gérard, Kuan-Yeh Huang, et al.
JHEP Reports : Innovation in Hepatology
|
July 18, 2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Clinical and Molecular Hepatology
|
October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C
Chun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Scientific Reports
|
June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
Mei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 234) with videos related to
Sort By:
Page
of 24
The Journal of Infectious Diseases
|
April 9, 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions
Chung-Feng Huang, Chao-Hung Hung, Pin-Nan Cheng, et al.
Science Advances
|
January 31, 2020
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
Kuan-Wei Huang, Fu-Fei Hsu, Jiantai Timothy Qiu, et al.
International Journal of Legal Medicine
|
June 17, 2010
The strategies to DVI challenges in Typhoon Morakot
Chun-Yen Lin, Tsun-Ying Huang, Hsuan-Cheng Shih, et al.
Nature Communications
|
October 27, 2022
GPR97 triggers inflammatory processes in human neutrophils via a macromolecular complex upstream of PAR2 activation
Tai-Ying Chu, Céline Zheng-Gérard, Kuan-Yeh Huang, et al.
JHEP Reports : Innovation in Hepatology
|
July 18, 2025
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
Clinical and Molecular Hepatology
|
October 4, 2023
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin-Nan Cheng, Wen-Jone Chen, Charles Jia-Yin Hou, et al.
JHEP Reports : Innovation in Hepatology
|
December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study
Pasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis C
Chun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Scientific Reports
|
June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients
Mei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Page
of 24